Question · asked by 1 review

RISPERIDONE vs ZIPRASIDONE ‒ long‐term data (> 12 months): Leaving the study early

Population
people with both severe mental illness and substance misuse
Intervention
RISPERIDONE
Comparison
ZIPRASIDONE ‒ long‐term data (> 12 months)
Outcome
Leaving the study early

RISPERIDONE showed no clear difference in leaving the study early: any reason compared with ZIPRASIDONE ‒ long‐term data (> 12 months) (low certainty).

What each review found

Include earlier review versions
FindingEffectStudiesGRADE certainty
RISPERIDONE vs ZIPRASIDONE ‒ long‐term data (> 12 months)
Leaving the study early: any reason · people with severe mental illness and co‐occurring substance misuse
RISPERIDONE showed no clear difference in leaving the study early: any reason compared with ZIPRASIDONE ‒ long‐term data (> 12 months) (low certainty).
Risperidone versus other antipsychotics for people with severe mental illness and co‐occurring substance… (2018) · Cochrane Headline outcomes only
RR 0.96 [0.85, 1.1]1 study · 240 participantsLow

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
Risperidone versus other antipsychotics for people with severe mental illness and co‐occurring substance misuse
2018 · Cochrane Headline outcomes only
Not reportedNot extractedNot assessed

The same intervention and outcome, asked in another population or against another comparator.

How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.